$BCRX
BIOCRYST PHARMACEUTICALS INC Stock $bcrx

$bcrx Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000162828023016458 Filed on May 08, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$82.49M	$68.78M	$49.92M
YoY Change	25.88%	37.77%	161.94%
Cost Of Revenue	$950.0K	$938.0K	$236.0K
YoY Change	286.18%	297.46%	-96.02%
Gross Profit	$81.54M	$67.84M	$49.69M
YoY Change	24.9%	36.53%	278.25%
Gross Profit Margin	98.85%	98.64%	99.53%
Selling, General & Admin	$51.00M	$47.87M	$34.28M
YoY Change	34.14%	39.63%	55.02%
% of Gross Profit	62.54%	70.56%	69.0%
Research & Development	$51.25M	$48.39M	$65.36M
YoY Change	-17.33%	-25.97%	54.02%
% of Gross Profit	62.85%	71.33%	131.54%
Depreciation & Amortization	$407.0K	$405.0K	$317.0K
YoY Change	21.49%	27.76%	78.09%
% of Gross Profit	0.5%	0.6%	0.64%
Operating Expenses	$102.2M	$96.26M	$99.64M
YoY Change	2.24%	-3.4%	54.37%
Operating Profit	-$20.70M	-$28.42M	-$49.96M
YoY Change	-40.37%	-43.12%	-2.76%
Interest Expense	-$24.86M	-$24.25M	$23.84M
YoY Change	-203.51%	-201.72%	84.73%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$74.59M	-$52.66M	-$73.92M
YoY Change	28.59%	-28.76%	14.99%
Income Tax	$740.0K	$671.0K	$279.0K
% Of Pretax Income
Net Earnings	-$75.33M	-$53.33M	-$74.20M
YoY Change	27.98%	-28.12%	15.42%
Net Earnings / Revenue	-91.31%	-77.54%	-148.62%
Basic Earnings Per Share	-$0.40	-$0.28	-$0.40
Diluted Earnings Per Share	-$0.40	-$0.28	-$401.3K
COMMON SHARES
Basic Shares Outstanding	188.9M shares	188.5M shares	184.9M shares
Diluted Shares Outstanding	189.1M shares	188.5M shares	184.9M

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$410.7M	$398.2M	$443.5M
YoY Change	-1.63%	-10.22%	84.5%
Cash & Equivalents	$146.2M	$155.1M	$395.5M
Short-Term Investments	$264.5M	$243.0M	$47.96M
Other Short-Term Assets	$15.69M	$16.62M	$15.69M
YoY Change	25.48%	5.95%	58.45%
Inventory	$27.03M	$27.47M	$16.14M
Prepaid Expenses
Receivables	$57.67M	$48.64M	$36.42M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$511.1M	$490.9M	$511.7M
YoY Change	3.27%	-4.07%	86.91%
LONG-TERM ASSETS
Property, Plant & Equipment	$8.438M	$8.376M	$8.799M
YoY Change	-3.03%	-4.81%	25.07%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$3.445M	$3.432M	$0.00
YoY Change
Other Assets	$6.946M	$7.046M	$7.207M
YoY Change	-0.53%	-2.23%	98.81%
Total Long-Term Assets	$18.83M	$18.85M	$16.01M
YoY Change	20.04%	17.79%	50.15%
TOTAL ASSETS
Total Short-Term Assets	$511.1M	$490.9M	$511.7M
Total Long-Term Assets	$18.83M	$18.85M	$16.01M
Total Assets	$529.9M	$509.7M	$527.7M
YoY Change	3.79%	-3.41%	85.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$13.89M	$6.254M	$13.88M
YoY Change	15.51%	-54.95%	2.6%
Accrued Expenses	$75.30M	$75.21M	$63.58M
YoY Change	-5.53%	18.29%	94.33%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$93.50M	$85.16M	$81.02M
YoY Change	-1.98%	5.11%	-19.94%
LONG-TERM LIABILITIES
Long-Term Debt	$293.2M	$232.5M	$140.2M
YoY Change	102.87%	65.81%	13.98%
Other Long-Term Liabilities	$5.803M	$5.934M	$6.457M
YoY Change	-6.37%	-8.1%	65.56%
Total Long-Term Liabilities	$293.2M	$232.5M	$140.2M
YoY Change	102.87%	65.81%	13.98%
TOTAL LIABILITIES
Total Short-Term Liabilities	$93.50M	$85.16M	$81.02M
Total Long-Term Liabilities	$293.2M	$232.5M	$140.2M
Total Liabilities	$386.7M	$317.7M	$221.3M
YoY Change	61.18%	43.58%	-1.33%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.583B	-$1.508B	-$1.282B
YoY Change	18.11%	17.65%	17.83%
Common Stock	$1.895M	$1.889M	$1.856M
YoY Change	1.94%	1.78%	4.45%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$388.7M	-$328.3M	-$164.2M
YoY Change
Total Liabilities & Shareholders Equity	$529.9M	$509.7M	$527.7M
YoY Change	3.79%	-3.41%	85.54%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$75.33M	-$53.33M	-$74.20M
YoY Change	27.98%	-28.12%	15.42%
Depreciation, Depletion And Amortization	$407.0K	$405.0K	$317.0K
YoY Change	21.49%	27.76%	78.09%
Cash From Operating Activities	-$18.81M	-$47.51M	-$77.80M
YoY Change	-32.22%	-38.93%	27.52%
INVESTING ACTIVITIES
Capital Expenditures	$467.0K	$160.0K	-$406.0K
YoY Change	-291.39%	-139.41%	306.0%
Acquisitions
YoY Change
Other Investing Activities	-$18.57M	-$106.9M	-$38.07M
YoY Change	-80.9%	180.96%	-357.73%
Cash From Investing Activities	-$19.04M	-$107.1M	-$38.47M
YoY Change	-80.46%	178.41%	-362.2%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	29.36M	$5.077M	$7.356M
YoY Change	19870.07%	-30.98%	153.66%
NET CHANGE
Cash From Operating Activities	-18.81M	-$47.51M	-$77.80M
Cash From Investing Activities	-19.04M	-$107.1M	-$38.47M
Cash From Financing Activities	29.36M	$5.077M	$7.356M
Net Change In Cash	-8.493M	-$149.6M	-$108.9M
YoY Change	-93.21%	37.44%	150.65%
FREE CASH FLOW
Cash From Operating Activities	-$18.81M	-$47.51M	-$77.80M
Capital Expenditures	$467.0K	$160.0K	-$406.0K
Free Cash Flow	-$19.28M	-$47.67M	-$77.39M
YoY Change	-29.92%	-38.4%	27.06%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000882796
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Statement Of Financial Position Extensible List DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AvailableForSaleSecuritiesDebtSecuritiesCurrent http://fasb.org/us-gaap/2022#LongTermInvestments
CY2022Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Statement Of Financial Position Extensible List DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AvailableForSaleSecuritiesDebtSecuritiesCurrent http://fasb.org/us-gaap/2022#LongTermInvestments
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2023Q1	us-gaap	Operating Lease Liability Statement Of Financial Position Extensible List OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	000-23186
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	BIOCRYST PHARMACEUTICALS, INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	62-1413174
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	4505 Emperor Blvd., Suite 200
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Durham
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	NC
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	27703
CY2023Q1	dei	City Area Code CityAreaCode	919
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	859-1302
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock
CY2023Q1	dei	Trading Symbol TradingSymbol	BCRX
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	188934787	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	155136000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	304767000	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1463000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1472000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	243022000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	119543000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	48639000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	50599000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	27466000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	27533000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	15157000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	12586000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	490883000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	516500000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8376000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8617000	usd
CY2023Q1	us-gaap	Long Term Investments LongTermInvestments	3432000	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	18077000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7046000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6806000	usd
CY2023Q1	us-gaap	Assets Assets	509737000	usd
CY2022Q4	us-gaap	Assets Assets	550000000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	6254000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	14356000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	75212000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	87565000	usd
CY2023Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1200000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1224000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2491000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2369000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	85157000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	105514000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5934000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5804000	usd
CY2023Q1	bcrx	Future Royalties Payable FutureRoyaltiesPayable	514411000	usd
CY2022Q4	bcrx	Future Royalties Payable FutureRoyaltiesPayable	501655000	usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	232522000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	231624000	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	188883000	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	188883000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	187906000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	187906000	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	1889000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1879000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1177192000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1158118000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	585000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	26000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1507953000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1454620000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-328287000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-294597000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	509737000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	550000000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	68778000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	49923000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	931000	usd
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	236000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	48388000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	65360000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	47867000	usd
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	34282000	usd
CY2023Q1	bcrx	Royalty Expense Reversal Of Expense RoyaltyExpenseReversalOfExpense	7000	usd
CY2022Q1	bcrx	Royalty Expense Reversal Of Expense RoyaltyExpenseReversalOfExpense	2000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	97193000	usd
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	99880000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-28415000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-49957000	usd
CY2023Q1	bcrx	Interest And Other Income Loss InterestAndOtherIncomeLoss	3378000	usd
CY2022Q1	bcrx	Interest And Other Income Loss InterestAndOtherIncomeLoss	54000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	27396000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	23837000	usd
CY2023Q1	us-gaap	Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments	-229000	usd
CY2022Q1	us-gaap	Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments	-177000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-52662000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-73917000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	671000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	279000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-53333000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-74196000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	59000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	78000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	500000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-69000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-52774000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-74187000	usd
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.28
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.28
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.40
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.40
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	188509000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	188509000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	184898000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	184898000	shares
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-53333000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-74196000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	405000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	317000	usd
CY2023Q1	us-gaap	Inventory Write Down InventoryWriteDown	236000	usd
CY2022Q1	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	14007000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	9601000	usd
CY2023Q1	bcrx	Noncash Interest Expense And Amortization Of Debt Issuance Costs NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts	20216000	usd
CY2022Q1	bcrx	Noncash Interest Expense And Amortization Of Debt Issuance Costs NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts	19003000	usd
CY2023Q1	bcrx	Amortization Of Discount And Premium On Investments AmortizationOfDiscountAndPremiumOnInvestments	-1385000	usd
CY2022Q1	bcrx	Amortization Of Discount And Premium On Investments AmortizationOfDiscountAndPremiumOnInvestments	30000	usd
CY2023Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-2019000	usd
CY2022Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	7048000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-131000	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	354000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2547000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2320000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-27226000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-22908000	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-35000	usd
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	75000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-47512000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-77800000	usd
CY2023Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	160000	usd
CY2022Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	406000	usd
CY2023Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	148637000	usd
CY2022Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	38066000	usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	41688000	usd
CY2022Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-107109000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-38472000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5077000	usd
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	7356000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5077000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7356000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-96000	usd
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	40000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-149640000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-108876000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	306239000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	507734000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	156599000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	398858000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-294597000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-53333000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	559000	usd
CY2023Q1	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	176000	shares
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1575000	usd
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	801000	shares
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3502000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14007000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-328287000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-106986000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-74196000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	9000	usd
CY2022Q1	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	115000	shares
CY2022Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1504000	usd
CY2022Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1108000	shares
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5853000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9601000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-164215000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	137620000	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. Significant estimates in the Company’s consolidated financial statements have been made relative to the calculation of net product sales, the ORLADEYO and Factor D inhibitors royalty financing obligations, inventory reserves, certain accruals, primarily related to the Company’s research and development expenses, the valuation of stock options and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</span></div>
CY2023Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	68778000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	49923000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	243022000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	119543000	usd
CY2023Q1	bcrx	Long Term Investment Maturity Minimum LongTermInvestmentMaturityMinimum	P12M
CY2023Q1	us-gaap	Inventory Adjustments InventoryAdjustments	236000	usd
CY2023Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1413000	usd
CY2023Q1	us-gaap	Advertising Expense AdvertisingExpense	4047000	usd
CY2022Q1	us-gaap	Advertising Expense AdvertisingExpense	3984000	usd
CY2023Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	27396000	usd
CY2022Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	23837000	usd
CY2023Q1	bcrx	Amortization Of Debt Financing Costs And Original Issue Discounts AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts	898000	usd
CY2022Q1	bcrx	Amortization Of Debt Financing Costs And Original Issue Discounts AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts	-167000	usd
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	21641000	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	28699000	shares
CY2023Q1	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax	0	usd
CY2022Q1	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax	0	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	68778000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	49923000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	246832000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	180000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	69000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	627000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	246454000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	138196000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	487000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1063000	usd
CY2023Q1	bcrx	Maturing After One Year Through Two Years MaturingAfterOneYearThroughTwoYears	3432000	usd
CY2022Q4	bcrx	Maturing After One Year Through Two Years MaturingAfterOneYearThroughTwoYears	18077000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	246454000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	137620000	usd
CY2023Q1	us-gaap	Receivables Net Current ReceivablesNetCurrent	1091000	usd
CY2022Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	8268000	usd
CY2023Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	8869000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	8906000	usd
CY2023Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	15613000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	14990000	usd
CY2023Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	4397000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	4814000	usd
CY2023Q1	us-gaap	Inventory Gross InventoryGross	28879000	usd
CY2022Q4	us-gaap	Inventory Gross InventoryGross	28710000	usd
CY2023Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1413000	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1177000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	27466000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	27533000	usd
CY2022Q4	bcrx	Future Royalties Payable FutureRoyaltiesPayable	501655000	usd
CY2023Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	usd
CY2023Q1	bcrx	Non Cash Interest Expense On Royalty Financing Obligation NonCashInterestExpenseOnRoyaltyFinancingObligation	19318000	usd
CY2023Q1	bcrx	Royalties Revenues Paid And Payable RoyaltiesRevenuesPaidAndPayable	-6562000	usd
CY2023Q1	bcrx	Future Royalties Payable FutureRoyaltiesPayable	514411000	usd
CY2023Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	7142000	usd
CY2022Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	4321000	usd
CY2023Q1	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	11930000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	898000	usd
CY2022Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	167000	usd
CY2023Q1	bcrx	Aggregate Lease Expense AggregateLeaseExpense	727000	usd
CY2022Q1	bcrx	Aggregate Lease Expense AggregateLeaseExpense	594000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y9M18D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y1M6D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.108
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.110
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7046000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6806000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2491000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2369000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5934000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5804000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	8425000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	8173000	usd
CY2023Q1	bcrx	Operating Lease Right Of Use Asset Accumulated Amortization OperatingLeaseRightOfUseAssetAccumulatedAmortization	4878000	usd
CY2022Q4	bcrx	Operating Lease Right Of Use Asset Accumulated Amortization OperatingLeaseRightOfUseAssetAccumulatedAmortization	4349000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	705000	usd
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	574000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	2137000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2175000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1711000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	824000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	613000	usd
CY2023Q1	bcrx	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	6161000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	13621000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	5196000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	8425000	usd
CY2023Q1	bcrx	Share Based Payment Arrangement Number Of Plans ShareBasedPaymentArrangementNumberOfPlans	3	plan
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14007000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9601000	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	139166000	usd
CY2023Q1	bcrx	Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized For Remainder Of Fiscal Year EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear	38098000	usd
CY2023Q1	bcrx	Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Next Year EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear	46800000	usd
CY2023Q1	bcrx	Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Two EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo	35358000	usd
CY2023Q1	bcrx	Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Three EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree	18689000	usd
CY2023Q1	bcrx	Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Four EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour	221000	usd
CY2023Q1	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	176000	shares
CY2022Q1	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	115000	shares

Files In Submission

Name	View Source	Status
bcrx-20230331_cal.xml	Edgar Link	unprocessable
bcrx-20230331_pre.xml	Edgar Link	unprocessable
0001628280-23-016458-index-headers.html	Edgar Link	pending
0001628280-23-016458-index.html	Edgar Link	pending
0001628280-23-016458.txt	Edgar Link	pending
0001628280-23-016458-xbrl.zip	Edgar Link	pending
bcrx-20230331.htm	Edgar Link	pending
bcrx-20230331.xsd	Edgar Link	pending
bcrx-20230331xexx311.htm	Edgar Link	pending
bcrx-20230331xexx312.htm	Edgar Link	pending
bcrx-20230331xexx321.htm	Edgar Link	pending
bcrx-20230331xexx322.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
bcrx-20230331_lab.xml	Edgar Link	unprocessable
bcrx-20230331_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
bcrx-20230331_htm.xml	Edgar Link	completed
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BCRX
BIOCRYST PHARMACEUTICALS INC Stock $bcrx

2023 Q2 Form 10-Q Financial Statement

#000162828023016458 Filed on May 08, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCRX BIOCRYST PHARMACEUTICALS INC Stock $bcrx

2023 Q2 Form 10-Q Financial Statement

#000162828023016458 Filed on May 08, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCRX
BIOCRYST PHARMACEUTICALS INC Stock $bcrx